Health Check: Additional Healthcare Reversals from Trump's Cost-Cutting Team

February 15, 2025 11:00 AM AEDT | By Team Kalkine Media

Health Check: Additional Healthcare Reversals from Trump's Cost-Cutting Team

Biotech Analysis: Cochlear and ResMed

Recent evaluations of biotech firms such as Cochlear (ASX:COH) and ResMed (ASX:RMD) highlight potential growth opportunities following underwhelming earnings results. Cochlear experienced a 7% profit increase yet faces market pressure over delays in product launches. Meanwhile, ResMed addresses concerns over new anti-obesity treatments potentially impacting demand for its sleep apnea solutions. Integral Diagnostics (ASX:IDX) also garners interest for its prospective growth in federal lung cancer screenings, suggesting a resurgence in the biotech sector.

Percheron's Leadership Retains Grip Amid Change Attempts

At Percheron, recent attempts to shift executive leadership faced resistance, with CEO James Garner and Chairman Dr. Charmaine Gittleson retaining their positions despite significant votes for change. The company's strategic direction remains under scrutiny following the setback of a failed Duchenne muscular dystrophy trial. However, Percheron looks ahead to potential new ventures and asset acquisitions, maintaining focus on broader growth and development.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.